# Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)

> **NCT04629144** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 48 (estimated)

## Conditions studied

- Vasculitis
- Cryoglobulinemia

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629144
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2025-04-20
- **Final completion:** 2025-10-20
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629144, "Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04629144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*